Taiwan
· Delayed Price · Currency is TWD Foresee Pharmaceuticals Statistics
Total Valuation
Foresee Pharmaceuticals has a market cap or net worth of TWD 10.75 billion. The enterprise value is 10.00 billion.
| Market Cap | 10.75B |
| Enterprise Value | 10.00B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Foresee Pharmaceuticals has 135.96 million shares outstanding. The number of shares has increased by 14.84% in one year.
| Shares Outstanding | 135.96M |
| Shares Change (YoY) | +14.84% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 2.81% |
| Owned by Institutions (%) | 2.71% |
| Float | 108.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.86 |
| PB Ratio | 10.75 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.64 |
| EV / Sales | 30.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -12.13 |
Financial Position
The company has a current ratio of 2.67, with a Debt / Equity ratio of 21.97.
| Current Ratio | 2.67 |
| Quick Ratio | 2.10 |
| Debt / Equity | 21.97 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -174.81 |
Financial Efficiency
Return on equity (ROE) is -61.48% and return on invested capital (ROIC) is -34.11%.
| Return on Equity (ROE) | -61.48% |
| Return on Assets (ROA) | -27.45% |
| Return on Capital (ROIC) | -34.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.23% in the last 52 weeks. The beta is 1.14, so Foresee Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -2.23% |
| 50-Day Moving Average | 80.45 |
| 200-Day Moving Average | 91.14 |
| Relative Strength Index (RSI) | 44.16 |
| Average Volume (20 Days) | 131,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Foresee Pharmaceuticals had revenue of TWD 327.18 million and -859.00 million in losses. Loss per share was -6.32.
| Revenue | 327.18M |
| Gross Profit | 163.53M |
| Operating Income | -859.18M |
| Pretax Income | -807.34M |
| Net Income | -859.00M |
| EBITDA | -797.67M |
| EBIT | -859.18M |
| Loss Per Share | -6.32 |
Balance Sheet
The company has 972.76 million in cash and 219.72 million in debt, giving a net cash position of 753.04 million or 5.54 per share.
| Cash & Cash Equivalents | 972.76M |
| Total Debt | 219.72M |
| Net Cash | 753.04M |
| Net Cash Per Share | 5.54 |
| Equity (Book Value) | 1.00B |
| Book Value Per Share | 7.36 |
| Working Capital | 835.42M |
Cash Flow
In the last 12 months, operating cash flow was -771.87 million and capital expenditures -52.39 million, giving a free cash flow of -824.27 million.
| Operating Cash Flow | -771.87M |
| Capital Expenditures | -52.39M |
| Free Cash Flow | -824.27M |
| FCF Per Share | -6.06 |
Margins
Gross margin is 49.98%, with operating and profit margins of -262.60% and -262.54%.
| Gross Margin | 49.98% |
| Operating Margin | -262.60% |
| Pretax Margin | -246.76% |
| Profit Margin | -262.54% |
| EBITDA Margin | -243.80% |
| EBIT Margin | -262.60% |
| FCF Margin | -251.93% |
Dividends & Yields
Foresee Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.84% |
| Shareholder Yield | -14.84% |
| Earnings Yield | -7.99% |
| FCF Yield | -7.66% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |